Category: Cannabis

Aurora Cannabis Sells Polaris Facility For $15 Million, After Spending $50 Million To Develop It

Aurora Cannabis (TSX: ACB) has finalized the losses on its Aurora Sky facility in Edmonton, revealing this morning that it has finally sold the facility, sixteen months after it announced the closure of the operation.

The facility has reportedly been sold for $15 million, crystallizing the major loss that the company has taken on the building. The development of the facility was announced in February 2019, with the 300,000 square foot facility slated to open months later in late 2019.

Two years after opening though, it was clear the company was not in need of the logistics and warehousing space that the building was intended to provide. Two years after opening, the facility in September 2021 was marked for closure as Aurora looked to streamline its operations in a toughening cannabis market.

For the year ended June 30, 2022, the firm took a $21.1 million impairment on the facility in connection with the closure, at the time leaving a value of $18.7 million on the books for the facility while at the same time classifying it as an asset held for sale. Additional impairments occurred in 2021 for the facility, however this figure was blended with other impairments that the company took during the fiscal year to the tune of $273.0 million, obfuscating the true impact that facility caused to the firms books.

Estimates on Alberta’s major projects page suggest that the facility itself cost approximately $50 million to develop. This figure would imply a loss of $35 million just on the development of the facility, and not including any related equipment within the building.

Going forward, Aurora is said to have a cash position of $320 million following the sale of the facility, a figure which includes $63 million in restricted cash. The firm also currently anticipates achieving adjusted EBITDA profitability for the quarter ended December 31, 2022.

Aurora Cannabis last traded at $1.25 on the TSX.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Tilray Brands Q3 Earnings Analysis: Behind The CEO’s “Robust” Claims

April 12, 2025, 03:28:00 PM

Tilray Q3 FY2025 Results: Shares Slump On 656% Wider Net Loss

April 10, 2025, 07:21:00 AM

Gold Flora Corp Files for Voluntary Receivership Amid Mounting Debt

March 31, 2025, 08:00:13 AM

SNDL Reports Record Annual Revenue in 2024, But Still Posts An Operating Loss

March 18, 2025, 11:29:00 AM

Simply Solventless To Acquire CanadaBis Capital For $0.116 A Share In All-Stock Deal

March 12, 2025, 09:08:11 AM

Trulieve Cannabis Sees Another CFO Resign

March 7, 2025, 08:48:47 AM

Curaleaf Reports $216M Net Loss in 2024 Despite $1.34B Revenue

March 4, 2025, 08:01:00 AM

Fetterman Launches Petition Drive for Federal Marijuana Legalization

February 26, 2025, 10:04:00 AM

Acting DEA Chief Says Cannabis Review Is Not Dead—Yet—as Successor Looms

February 12, 2025, 12:47:00 PM

Aurora Cannabis Rallies On 316% Earnings Jump In Q3 2025

February 9, 2025, 11:28:00 AM
Video Articles

Teck Resources Q1 Earnings: Defying Copper Industry Weakness

Equinox Ups Its Offer For Calibre: Investors Said No!

First Quantum Q1 Earnings: Copper Major Still Bleeding Cash

Recommended

Verses Hits Commercialization Stage With Genius AI Platform

Cardiol Sees First Patient Enrolled Under Phase III MAVERIC Clinical Trial